SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
NCT07850050 on ClinicalTrials.gov · last registry update 2026-10-14
Registered but not yet open, with 600 participants planned. Due to report 26 July 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Percentage change in body weight from baseline to Week 52. Sponsors move these dates routinely; any movement since this site started watching is listed below. survodutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- survodutide
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Enrollment
- 600
- Started
- 2026-10-31
- Primary completion
- 2028-07-26 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-30 | First seen in registry | Registered as NOT_YET_RECRUITING, P3 |
Primary outcome
Percentage change in body weight from baseline to Week 52
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the survodutide page for this molecule’s full trial and approval history.